Leisure Capital Management Sells 822 Shares of Amgen Inc. (NASDAQ:AMGN)

Leisure Capital Management decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 13.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,411 shares of the medical research company’s stock after selling 822 shares during the quarter. Leisure Capital Management’s holdings in Amgen were worth $1,558,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Consolidated Planning Corp acquired a new position in Amgen during the fourth quarter worth about $210,000. Alexander Randolph Advisory Inc. acquired a new position in shares of Amgen in the fourth quarter valued at approximately $2,079,000. Valmark Advisers Inc. increased its stake in shares of Amgen by 0.6% in the fourth quarter. Valmark Advisers Inc. now owns 8,036 shares of the medical research company’s stock valued at $2,315,000 after buying an additional 45 shares during the period. Addison Advisors LLC increased its stake in shares of Amgen by 127.5% in the fourth quarter. Addison Advisors LLC now owns 1,176 shares of the medical research company’s stock valued at $339,000 after buying an additional 659 shares during the period. Finally, Gilliland Jeter Wealth Management LLC acquired a new stake in Amgen during the 4th quarter valued at approximately $421,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. The Goldman Sachs Group increased their target price on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Morgan Stanley lowered their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. TD Cowen decreased their target price on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, Oppenheimer reissued an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. Ten analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Amgen has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Stock Up 0.2 %

Shares of NASDAQ AMGN traded up $0.60 during mid-day trading on Friday, hitting $269.98. 2,436,959 shares of the stock traded hands, compared to its average volume of 2,035,139. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company has a market cap of $144.81 billion, a price-to-earnings ratio of 21.62, a PEG ratio of 2.60 and a beta of 0.58. The stock has a fifty day moving average price of $275.10 and a 200-day moving average price of $281.45.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the previous year, the company posted $4.09 earnings per share. Research analysts anticipate that Amgen Inc. will post 19.43 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is currently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.